UPDATED: Catalent slashing jobs in U.K.

Catalent is cutting 45 jobs from its Swindon, U.K., facility, a move the company told a local newspaper is part of a restructuring effort at the site.

The Swindon Advertiser reports that Catalent has already shed temporary staff at the facility and informed the affected employees last week. A Catalent spokesperson told the paper it is responding to "changes in volume demand" at the 158,000-square-foot plant and plans to work with the impacted staff and provide "all necessary assistance."

The 500-employee facility houses development and manufacturing for Catalent's Zydis quick-dissolve tablet, and Catalent has recently launched a chemistry, manufacturing and control lab services unit at the site. Which of those two business faces shrinking demand remains unclear, and a Catalent spokesperson declined to elaborate on the statement Monday.

According to the Advertiser, Catalent cut 50 jobs at the facility in 2010 as part of an effort to trim staffing by 275 company-wide.

The Catalent cuts are another blow to Swindon's pharmaceutical sector; CMO Patheon ($PTI) announced in May that it will gradually wind down production at its plant there. Patheon tried in vain to sell the facility and now plans to get what it can out of the plant over the next couple years before transferring all of its capacity to other locations.

- read the story
- get more from FiercePharmaManufacturing

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.